Products


Latest News

Opto Global is pleased to announce that Optos, a leading medical retinal imaging company, has recently acquired Opto Global. Optos designs, develops, manufactures and markets retinal imaging devices that create optomap images. The optomap is the only image that provides an ultra-widefield view of
Opto Global will be exhibiting at the upcoming APAO Congress as a subsidiary of Optos, occupying booths 337 and 338. The exhibition will be held in Sydney’s Darling Harbour Convention and Exhibition Centre between the 20th and 24th of March 2011. Optos/ Opto Global will be displaying leading

Newsletter Signup

Name:








Ribolink™

Ribolink™ (riboflavin) must be used during every corneal collagen cross-linking procedure. The Vitamin B2 included in Ribolink™ acts as a blocking agent for potentially harmful UV-A rays during the procedure.

UV radiation in combination with Riboflavin initiates molecular cross-linking of corneal collagen. Thus progressive corneal thinning is slowed down or even stopped. Biomechanical strength of corneal tissue is improved.

Highlights

The Ribolink™ is offered as a single-use presentation. Available in:

  • Ribolink™ Isotonic – Riboflavin 5-phosphate (0.1%) plus 20% Dextran T500 in 3ml syringe
  • Ribolink™ Hypotonic – Riboflavin 5-phosphate (0.1%) in 1ml syringe

Ribolink™ is produced and packaged in Australia by a “Class II” manufacturing Pharmacy under aseptic conditions, and is supplied in sterile packaging.

Convenient packaging and applicator.

 

Opto Ribolink™ is not FDA approved. This product is not for sale in the USA.

 

Clinical Applications

A number of clinical studies have demonstrated that progressive keratoconus and iatrogenic ectasia can be stabilized by corneal cross-linking. The riboflavin solution (0.1% in dextran) is administered during conservative parasurgical procedures for keratoconus and other corneal ectasia pathologies. It is claimed this treatment can prevent the necessity of corneal transplant.